Welcome to our dedicated page for Tabula Rasa HealthCare news (Ticker: TRHC), a resource for investors and traders seeking the latest updates and insights on Tabula Rasa HealthCare stock.
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC) is a leading healthcare company that specializes in personalized, comprehensive care for value-based care organizations. The company offers innovative service models and cutting-edge healthcare technology solutions that improve patient outcomes and maximize provider efficiency. Headquartered in Moorestown, New Jersey, TRHC focuses on optimizing medication management and delivering precise, individualized care to at-risk populations.
TRHC's core services include comprehensive pharmacy services, personalized medication management, and a suite of clinical and business management tools. These tools help health plans and provider groups optimize utilization and improve patient health. The company's technology-enabled solutions are designed to reduce risk, enhance medication efficacy, and improve overall healthcare efficiencies.
In recent developments, TRHC has entered into a definitive agreement to be acquired by Nautic Partners for $10.50 per share in cash, valuing the company at approximately $570 million. This acquisition is set to combine TRHC with ExactCare Pharmacy, another portfolio company of Nautic, enhancing the reach and capabilities of both entities. The merger is expected to close in the fourth quarter of 2023, subject to customary closing conditions.
TRHC's recent financial performance has been strong, with significant organic growth in its core PACE (Program of All-Inclusive Care for the Elderly) market. The company has focused on developing and expanding partnerships with risk-bearing healthcare organizations, aiming to serve the most complex care needs. This strategic focus has led to impressive financial results and increased profitability.
For those interested in the latest updates, TRHC will hold a conference call and webcast to discuss its second quarter 2023 financial results on August 8, 2023. The company continuously updates its stakeholders through its Investor Relations section on its website, providing access to financial results, earnings calls, and other significant announcements.
Tabula Rasa HealthCare (NASDAQ: TRHC) will hold a conference call on August 6, 2021, at 8:30 a.m. EDT to discuss its second quarter 2021 operating results. Financial results for the quarter ending June 30, 2021 will be released after the market closes on August 5, 2021. The call will feature CEO Calvin Knowlton, Co-Founder Orsula Knowlton, and CFO Brian Adams. Investors can join via phone or access a live audio webcast on the company’s Investor Relations website.
Tabula Rasa HealthCare (NASDAQ: TRHC) has appointed two healthcare executives to strengthen its leadership team. Kelli Kovak, RPh, joins as Executive Vice President, bringing a track record of significant revenue growth from her previous role at UnitedHealth Group. Pamela M. Lincoln-Giang, PharmD, takes on the role of Senior Director in the Office of Strategic Growth, focused on enhancing the company's MedWise HealthCare division. These appointments aim to support TRHC's growth and commitment to medication safety solutions, capitalizing on the expertise of the new leaders.
Tabula Rasa HealthCare (TRHC) has signed agreements with four additional state pharmacy associations, bringing the total to 12. This partnership aims to enhance medication safety through the use of TRHC's MedWise® technology, which identifies multi-drug interactions. The newly added states are California, Arizona, Michigan, and Washington. The initiative includes educational programs and access to the Certified MedWise Advisor™ program, which enhances pharmacists' capabilities in preventing adverse drug events (ADEs).
Tabula Rasa HealthCare (TRHC) has launched the MedWise Risk Level™, enhancing its PrescribeWellness Patient Engagement Center. This innovative tool helps pharmacists identify patients at risk for adverse drug events (ADEs), facilitating personalized medication support. The MedWise Risk Level is offered at no cost to PrescribeWellness customers, building on the previously introduced MedWise Risk Score™. The aim is to reduce hospital visits caused by medication issues and improve patient outcomes through advanced medication decision support.
Tabula Rasa HealthCare, Inc. (TRHC) announced record growth in its CareKinesis pharmacy services for the PACE program. In June 2021, the company achieved a 7% organic growth in new enrollment compared to the previous year and saw a significant surge in net enrollment during Q2, approximately ten times that of Q1. Legislative support in states like California and Florida aims to enhance PACE access, with Florida allocating over $73 million to support an increased participant base. TRHC’s solutions focus on optimizing medication safety and improving patient outcomes.
Tabula Rasa HealthCare (TRHC) has announced a five-year contract renewal with ArchCare Senior Life to provide pharmacy and medication management services. ArchCare serves over 700 participants in the New York metro region and will continue using TRHC's MedWise technology to identify multi-drug interactions and improve medication safety. This partnership has been instrumental in enhancing ArchCare's pharmacy practices and patient outcomes. TRHC's solutions, including MedWise, aim to combat medication overload and reduce adverse drug events, which are significant concerns in healthcare.
On May 24, 2021, Tabula Rasa HealthCare (TRHC) reported a surge in interest for new PACE (Program of All-Inclusive Care for the Elderly) projects in 2021. This rise is driven by new sponsors from various sectors joining traditional healthcare providers. The National PACE Association highlighted state-level initiatives to expand PACE programs, supported by federal policies including a $13 billion funding increase through the American Rescue Plan Act. TRHC's CareVention division emphasizes its expertise in PACE solutions, catering to over 90 percent of PACE plans.
Tabula Rasa HealthCare (TRHC) announced a significant clinical study collaboration with Regence Health Plans, revealing the effectiveness of its MedWise medication risk score in evaluating drug safety without risking patient harm. The study, published in Clinical and Translational Science, analyzed data from 500,000 members, demonstrating MedWise's ability to predict potential adverse drug events when adding COVID-19 treatment drugs. TRHC's technology aims to enhance patient safety by identifying patients at higher risk for adverse events, ultimately improving healthcare outcomes and reducing costs.
Tabula Rasa HealthCare (TRHC) reported its Q1 2021 financial results, achieving total revenue of $76.7 million, up 5% from $72.8 million in 2020. Notable highlights include a return to strong PACE enrollment growth, with a backlog of 48 new expansion centers and expected annual revenue potential exceeding $70 million. However, the company posted a GAAP net loss of $19.5 million, wider than last year's loss of $14.4 million. The outlook for Q2 estimates revenues between $80.5 million and $82.5 million, with ongoing investments in sales and marketing to drive growth.
Tabula Rasa HealthCare (NASDAQ: TRHC) will discuss its first quarter 2021 operating results in a conference call on May 7, 2021, at 8:30 a.m. EDT. Financial results will be released after market close on May 6, 2021. The call will feature CEO Calvin H. Knowlton, Co-Founder Orsula V. Knowlton, and CFO Brian W. Adams. Investors can access the webcast via TRHC's investor relations website. A replay will be available for 7 days following the call, and an audio archive will be accessible for 90 days.
FAQ
What is the market cap of Tabula Rasa HealthCare (TRHC)?
What does Tabula Rasa HealthCare, Inc. do?
Where is Tabula Rasa HealthCare headquartered?
What recent acquisition involves Tabula Rasa HealthCare?
What are the core services provided by TRHC?
How does TRHC improve patient care?
What is PACE and how is TRHC involved?
What were TRHC's recent financial results?
When is TRHC's next financial results call?
What is the significance of TRHC's merger with ExactCare Pharmacy?